Living With Multiple Myeloma: Bone Protection, Kidney Care and Staying Active Safely

A retired schoolteacher stands in her kitchen, one hand on the counter, deciding whether to lift the kettle with the other. Six months ago she would not have thought about it. Now she knows there is a thin patch in the bone of her upper arm, and the question of what is safe to pick up has quietly entered every hour of her day.

That hesitation is one of the least discussed parts of multiple myeloma, a cancer of plasma cells in the bone marrow. The disease is treated by hematologists, but much of the living happens in kitchens, on stairs and in the pharmacy aisle where an ordinary painkiller might be the wrong choice for a kidney under strain.

Bone health in multiple myeloma, kidney protection and movement are linked more tightly than most people realize. This explainer walks through what the evidence actually supports, what the treating team weighs when they make decisions, and where a patient’s own daily choices genuinely matter.

Why bone health in multiple myeloma needs its own plan

Healthy bone is never still. Two cell types keep it in balance: osteoclasts, which dissolve old bone, and osteoblasts, which lay down new bone. Across a lifetime the skeleton is rebuilt many times over, and most people never notice.

Myeloma tips that balance. Plasma cells are white blood cells that normally make antibodies; in myeloma, abnormal plasma cells multiply inside the marrow and release signals that switch osteoclasts on and hold osteoblasts back. Bone is removed faster than it can be replaced. The result is the pattern seen on scans as lytic lesions, which are punched-out areas where bone has thinned, along with a general loss of density that makes fractures more likely even without a fall.

Mayo Clinic lists bone pain and fractures among the common features of the disease, and the spine, ribs, pelvis and long bones of the arms and legs are the sites most often involved. The spine matters most because a collapsing vertebra can press on nerves or the spinal cord.

This is why bone health in multiple myeloma is not a side note to cancer treatment. Controlling the myeloma itself is the most powerful bone protection, because fewer abnormal plasma cells means fewer of the signals driving osteoclasts. Around that core, teams add three further layers: medicines that slow bone breakdown, local treatments for bones that are already damaged or at risk of breaking, and daily habits that reduce the load on weakened areas while keeping the rest of the body strong. Each layer has its own evidence, its own trade-offs and its own timeline, and the sections that follow take them in turn.

What multiple myeloma bone pain usually means, and when it does not

Pain is often the symptom that first brings myeloma to attention, and it remains the one people ask about most after diagnosis. The NHS describes it as a persistent dull ache, typically in the back, ribs or hips, that tends to be worse with movement and may not settle with rest in the way muscular pain does.

Not every ache is the disease advancing. People with myeloma also get the ordinary backaches, stiff necks and sore knees that anyone their age might have, and treatment itself can cause aches: bone-strengthening infusions sometimes produce a flu-like soreness for a day or two, and some myeloma drugs cause nerve pain in the hands and feet that patients may mistake for bone pain.

What distinguishes bone pain that needs attention is usually its character and its company. Pain that is new, sharply localized, sudden, or accompanied by a change in how a limb or the spine feels or works deserves a call to the team rather than a wait-and-see approach. A vertebral fracture can occur with no more force than a cough or a step off a curb.

Pain control in myeloma is a team responsibility. Radiotherapy to a painful lesion, adjustments to myeloma treatment and prescribed analgesics all have a role, and the choice among them depends on scan findings and kidney function. What patients should know is that one common class of over-the-counter painkillers, the non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen), can reduce blood flow through the kidneys and is generally approached with caution in myeloma. Any painkiller, including familiar ones, is worth checking with the pharmacist or hematology nurse first.

How bisphosphonates for myeloma and other bone-modifying drugs work

Two classes of medicine are used to slow bone loss in myeloma, and both act on the osteoclast, the cell that dissolves bone.

Bisphosphonates are drugs that bind tightly to the mineral surface of bone. When an osteoclast begins dissolving that surface, it absorbs the drug and its activity is switched off. In myeloma the intravenous forms are used most often; zoledronic acid and pamidronate are the generic names patients will hear. Because these drugs are cleared through the kidneys, the treating team checks kidney function before each infusion and may adjust the schedule or pause treatment when function drops. A day or two of flu-like aching after the first few infusions is common and usually fades with later doses.

Denosumab is a monoclonal antibody, a laboratory-made protein designed to block a single target. Its target is RANKL, the signal myeloma cells use to activate osteoclasts. Because it is not cleared by the kidneys, it is sometimes chosen when kidney function is impaired. Its main drawback is that it can lower blood calcium, so calcium and vitamin D levels are monitored and often supplemented under supervision.

Both classes reduce what clinicians call skeletal-related events: fractures, spinal cord compression, and the need for radiotherapy or surgery to bone. Neither reverses damage already done, and neither treats the myeloma itself. They are supportive, given alongside cancer treatment, and Mayo Clinic describes them as a standard part of care for myeloma affecting bone.

How long they continue is a clinical judgment. Guidelines generally describe courses measured in years with regular review, and the decision to continue, lengthen the interval or stop always sits with the prescribing hematologist.

Who is usually offered bone protection, and who is asked to wait

Bone-modifying treatment is generally offered to people with active myeloma that requires treatment, particularly when scans already show lytic lesions, thinning or a fracture. In practice most people starting myeloma therapy fall into this group, because bone involvement is one of the defining features of the disease.

Some people are asked to wait. The clearest example is smoldering myeloma, an early stage in which abnormal plasma cells are present but are not yet causing organ or bone damage. Here the standard approach is active monitoring rather than treatment, and bone-modifying drugs are not routinely started because the risks of long-term therapy are not yet balanced by a clear benefit. The same applies to MGUS, a precursor condition in which an abnormal protein is found in the blood without myeloma.

Other reasons to delay or modify the plan include:

• Kidney function below the level at which a particular bisphosphonate is considered safe, in which case the team may switch class, extend the interval, or wait for function to improve with myeloma treatment.
• Dental work that is planned or in progress, since invasive procedures are usually completed and healed before treatment begins.
• Low blood calcium that needs correcting first, especially before denosumab.
• Pregnancy, where the risk to the developing baby outweighs the benefit.

Waiting is not the same as doing nothing. People in the monitoring group are usually seen and scanned at intervals so that any change in bone status is caught early, and the ordinary protections of movement, fall prevention and dental care apply throughout. The recurring theme is that the timing of bone protection is individual, decided by the treating team on the basis of disease activity, kidney function and the person’s other health conditions.

Dental care before and during bone-strengthening treatment

One of the more surprising conversations at a myeloma clinic concerns teeth. The reason is a rare but serious complication of both bisphosphonates and denosumab called osteonecrosis of the jaw, in which an area of jawbone is exposed and fails to heal, usually after a tooth extraction or other procedure that breaks the gum.

The mechanism follows from how the drugs work. By slowing osteoclasts they also slow the constant remodeling that lets the jaw heal after injury. The jaw is unusually vulnerable because it sits beneath a thin layer of gum in a mouth full of bacteria and is disturbed every time someone chews. Cleveland Clinic and Mayo Clinic both list jaw osteonecrosis among the risks patients should be told about, and both note it is uncommon.

The practical response is straightforward and largely in the patient’s hands:

• A full dental check before starting treatment, so that any teeth likely to need extraction can be dealt with first and given time to heal.
• Regular dental visits during treatment, with the dentist told which drug is being used.
• Careful daily brushing and flossing, and prompt attention to any loose tooth, sore gum, or area of exposed bone.
• Well-fitting dentures, since pressure sores under an ill-fitting plate can be an entry point.

When a dental procedure becomes unavoidable during treatment, the dentist and hematologist usually talk to each other about timing. Some teams pause bone-modifying treatment around the procedure; others do not, because the drug stays in bone for a long time and a short pause may not change the risk. There is no single right answer in the evidence, and the decision is made case by case.

A sore jaw that does not settle, numbness in the lower lip, or a feeling of roughness inside the mouth are worth mentioning early. Caught quickly, most cases are managed conservatively.

Calcium, vitamin D and the high-calcium problem

Advice about calcium in myeloma can feel contradictory, and the confusion is understandable. The same disease that thins bone can also cause dangerously high blood calcium, and the medicines that protect bone can push calcium too low.

The high-calcium problem comes first. When myeloma dissolves bone faster than normal, calcium leaks into the bloodstream. Mayo Clinic lists hypercalcemia, the medical term for high blood calcium, among the complications of the disease. It causes thirst, frequent urination, constipation, nausea, confusion and drowsiness, and it is hard on the kidneys because it pulls water out of the body and can deposit in kidney tissue. Hypercalcemia is treated urgently in hospital with fluids and bone-modifying drugs, and it usually signals that the myeloma itself is active.

The low-calcium problem arrives with treatment. Denosumab in particular, and bisphosphonates to a lesser degree, can drive calcium down by switching off the bone breakdown that had been supplying it. This is why teams check calcium and vitamin D before and during treatment and often prescribe supplements to keep both in a safe range. Vitamin D matters because the body cannot absorb calcium from food efficiently without it, as the NIH Office of Dietary Supplements explains.

The practical message is that calcium and vitamin D supplements in myeloma are a prescription decision, not a self-care one. Taking extra calcium during a period of hypercalcemia could worsen it; skipping prescribed calcium during denosumab could allow a dangerous dip. Blood tests, not guesswork, guide the amounts.

Food remains a sensible baseline. Dairy, fortified plant milks, leafy greens, canned fish with bones and fortified cereals supply calcium; oily fish, egg yolks and fortified foods supply some vitamin D, with sunlight on skin providing the rest. The team will say whether diet alone is enough at each stage.

When a bone needs more than medicine

Bone-modifying drugs slow future damage. They do not fix a lesion that has already weakened a bone to the point of breaking, and they do not relieve pressure on a nerve. For those situations, three local treatments are used, each with a specific purpose.

Radiotherapy delivers focused radiation to a painful or threatening lesion. Myeloma cells are sensitive to it, and a short course can shrink a deposit, reduce pain and allow the bone around it to strengthen. The NHS describes radiotherapy as a treatment for bone pain and for areas at risk of fracture, and it is also the usual first response when a spinal deposit begins to press on the spinal cord.

Vertebroplasty and kyphoplasty are procedures for a vertebra that has collapsed. In vertebroplasty, bone cement is injected into the fractured vertebra to stabilize it. In kyphoplasty, a small balloon is inflated first to restore some of the height before the cement goes in. Both are done through a needle under imaging guidance rather than open surgery, and both are chosen mainly for pain that has not settled with other measures. They do not treat the myeloma and are not suitable for every fracture pattern.

Orthopedic surgery has a role when a long bone such as the femur has fractured or is judged likely to fracture. A rod or plate may be placed to hold the bone stable while radiotherapy and myeloma treatment address the underlying cause. Surgeons weigh the size and location of the lesion against the risks of an operation in someone who may have low blood counts or reduced kidney function.

Who gets which treatment is a multidisciplinary decision involving the hematologist, radiation oncologist, radiologist and often a spinal or orthopedic surgeon, with the patient’s goals for pain relief and mobility at the center.

How myeloma kidney damage happens

The kidney is the second organ most affected by myeloma, and the two problems are connected at the level of the bone itself.

Abnormal plasma cells produce large amounts of a single antibody or a fragment of one. The fragments are called light chains, small proteins that pass easily through the kidney’s filters and into the tubules, the fine channels that concentrate urine. In the tubules they can clump together into casts that block flow and inflame the surrounding tissue. Clinicians call this cast nephropathy, or myeloma kidney, and it is the most common way the disease damages kidney function. Light chains in the urine are sometimes still referred to by their historical name, Bence Jones protein.

Hypercalcemia adds a second injury. High blood calcium causes dehydration by increasing urine output, and dehydration concentrates the light chains in the tubules and makes casts more likely. A third source of harm is external: medicines and substances that reduce kidney blood flow or are toxic to tubules, including NSAIDs, some antibiotics and the iodinated contrast dyes used in certain CT scans.

Mayo Clinic and Cleveland Clinic both list kidney problems among the recognized complications of multiple myeloma, and reduced kidney function is often present at the time of diagnosis. The encouraging part of the evidence is that kidney function frequently improves once myeloma treatment lowers the light chain load, especially when treatment starts promptly and the kidneys are kept well perfused with fluids in the meantime.

Kidney function is tracked by a blood test for creatinine, a waste product the kidneys should clear, from which an estimated filtration rate is calculated. Patients see these numbers at nearly every visit, and it is reasonable to ask what the trend means rather than focusing on a single result.

Everyday kidney care: fluids, painkillers and scan dyes

Kidney protection in myeloma is one of the areas where daily habits carry real weight. The principle is simple: keep the light chains dilute, and keep anything that stresses the tubules out of the way.

Fluids come first. Well-hydrated kidneys pass light chains through rather than letting them stack into casts. The NHS advises people with myeloma to drink plenty of fluids to help the kidneys, and most teams give an individual daily target that accounts for heart health, other conditions and the current state of the kidneys. The target is not the same for everyone, and people with heart failure in particular need a personalized figure rather than a general one. Water, diluted juice and decaffeinated drinks all count. Alcohol does not help and can dehydrate.

Painkillers come second. NSAIDs, the class that includes ibuprofen, naproxen and high-dose aspirin, narrow the small vessels that supply the kidney’s filters and are usually avoided or used only with the team’s agreement. Paracetamol, known as acetaminophen in the US, is generally the preferred over-the-counter option, though the team should still know it is being taken. Some herbal and sports supplements also affect the kidneys and are worth mentioning.

Contrast dye comes third. CT scans and some angiography procedures use iodinated contrast that is cleared by the kidney and can worsen function in someone already at risk. This does not mean such scans are forbidden; it means the person ordering the scan should know about the myeloma so that alternatives, extra fluids or a different protocol can be considered.

Finally, treat infections early. Vomiting and diarrhea dehydrate quickly, and a fever in someone with myeloma is a reason to call the team the same day rather than wait it out.

Bone and kidney protection at a glance

The measures below draw together the advice in the preceding sections. None replaces the plan agreed with the treating team, and several, marked as prescription decisions, should not be started or stopped without it.

Measure	Mainly protects	How it helps	Who decides
Myeloma treatment itself	Bone and kidney	Fewer abnormal plasma cells means fewer bone-dissolving signals and fewer light chains	Hematology team
Bisphosphonate or denosumab	Bone	Switches off osteoclasts, reducing fractures and other skeletal events	Hematology team, with kidney and calcium checks
Dental check and oral hygiene	Jaw bone	Lowers the chance of osteonecrosis of the jaw	Patient and dentist, informed by the team
Calcium and vitamin D	Bone	Supports mineralization and prevents low calcium on treatment	Prescription decision guided by blood tests
Daily fluid target	Kidney	Keeps light chains dilute and reduces cast formation	Team sets target; patient carries it out
Avoiding NSAIDs	Kidney	Preserves blood flow to the filtering units	Patient, with pharmacist advice
Flagging myeloma before contrast scans	Kidney	Allows safer imaging choices	Patient and ordering clinician
Low-impact activity and fall prevention	Bone and general health	Maintains muscle and balance without loading weak areas	Physiotherapist and patient
Radiotherapy, kyphoplasty, surgery	Specific damaged bones	Relieves pain, stabilizes, relieves nerve pressure	Multidisciplinary team

Two patterns stand out in the table. First, the single most protective measure for both organs is effective treatment of the myeloma, which is why supportive care never substitutes for it. Second, the measures in a patient’s own hands are concentrated on the kidney side: fluids, painkiller choices and speaking up before scans. On the bone side, the patient’s biggest contributions are dental diligence and how they move, which the next sections cover.

Is exercise with multiple myeloma safe?

The instinct after a diagnosis that involves fragile bones is to move less. The evidence points the other way, with an important qualification about how.

Muscle supports bone. Strong thigh and trunk muscles take load off the spine and hips and, more importantly, keep balance and reaction time sharp so that trips do not become falls. Inactivity does the reverse: muscle wastes quickly during bed rest, bone density falls further, blood clots become more likely, and fatigue deepens. For people already dealing with myeloma-related tiredness and the side effects of treatment, that spiral is worth avoiding.

The CDC’s general guidance for adults describes 150 minutes a week of moderate activity plus two sessions of muscle strengthening as the target for health. For someone with myeloma that figure is a direction of travel, not a starting point, and the specifics depend on what the scans show. Someone with a lytic lesion in the femur or a recent vertebral fracture will have very different limits from someone whose bones look stable on imaging and whose disease is well controlled.

What most teams agree on:

• Walking, stationary cycling and swimming are usually well tolerated.
• Heavy lifting, high-impact activity, contact sports and movements that twist or load the spine under weight are generally avoided or cleared individually.
• Strength work should be introduced by a physiotherapist who has seen the imaging.
• Activity should be paused on days of fever, low blood counts flagged by the team, or new pain.

The single most useful step is a referral to a physiotherapist or exercise professional experienced in cancer care. They can translate a scan report into a list of movements to do and to avoid, which is far more reassuring than a general instruction to be careful.

What the first weeks of an activity plan usually look like

There is no single timeline, because myeloma arrives in people of different ages and fitness levels, sometimes with a fracture and sometimes without. Even so, the shape of a typical progression is recognizable, and knowing it helps set expectations.

In the first days after diagnosis or after a fracture, the priority is stability and pain control. If a vertebra has collapsed or a long bone is at risk, movement may be restricted until radiotherapy, a brace, or a stabilizing procedure has done its work. Gentle movement of unaffected joints, sitting out of bed and short assisted walks are usually encouraged even during this phase, because the harms of complete rest accumulate fast.

Over the following weeks, as treatment starts to lower the disease burden and pain eases, the physiotherapist typically introduces a walking program measured in minutes rather than distance, with a target that increases gradually as tolerance allows. Balance work, such as standing on one leg while holding a counter, comes early because falls are the main threat to a weakened skeleton.

Strengthening usually follows once the team is confident the bones can take it. This tends to mean body-weight and resistance-band exercises for the legs and trunk rather than gym machines, and it progresses slowly. Trunk-strengthening exercises are chosen carefully to avoid forward bending under load, which stresses the front of the vertebrae.

Fatigue is the variable that most often disrupts the plan. Treatment cycles, low blood counts and poor sleep all take their toll, and good plans build in easier weeks rather than pushing through. Mayo Clinic and the NHS both describe fatigue as one of the commonest symptoms of myeloma and its treatment; pacing is a skill, not a failure.

The result, over months rather than weeks, is usually a person who moves more confidently than they did in those first uncertain days in the kitchen.

Preventing falls and protecting the spine at home

Most fractures in myeloma happen with little or no trauma, but a fall converts a fragile bone into a broken one with certainty. Fall prevention is therefore not a topic for older adults alone; it applies to anyone whose bones the disease has thinned.

The home is where most falls happen, and small changes remove most of the risk. Loose rugs, trailing cables and clutter on stairs are the usual culprits. Good lighting matters, especially between bed and bathroom at night, since several myeloma treatments increase urination or cause dizziness on standing. Non-slip mats in the bath and a grab rail near the toilet cost little effort to install. Footwear with a closed heel and a grippy sole is safer than slippers or socks on a hard floor.

Some myeloma drugs cause peripheral neuropathy, nerve damage that numbs the feet and blunts the sense of where the ground is. People with neuropathy should mention it to the physiotherapist, because balance training and sometimes a walking aid make a real difference. Steroids, commonly used in myeloma treatment, can weaken thigh muscles over time and make rising from a low chair harder; a firmer, higher seat helps.

Spine protection is about mechanics. Lifting from the floor with a bent back and straight legs concentrates force on the front of the vertebrae. Bending the knees, keeping the load close to the body, and avoiding twisting while carrying something spreads the load. Reaching to a high shelf while looking up can also strain a weakened neck; a step stool with a handle is safer than a stretch.

Sleep positions matter too. A supportive mattress and a pillow that keeps the neck level reduce overnight strain, and getting out of bed by rolling to the side and pushing up with the arms avoids the sit-up motion that loads the lumbar spine.

What people often get wrong

Some of the most persistent misunderstandings around bone health in multiple myeloma come from well-meaning advice that would be right for a different condition.

The first is that more calcium always helps. In osteoporosis that is broadly true; in myeloma, blood calcium can be dangerously high when the disease is active, and adding supplements without checking a blood level can make matters worse. Calcium and vitamin D in myeloma follow the test results, not a general rule.

The second is that bone-strengthening drugs rebuild bone. They do not. Bisphosphonates and denosumab slow the loss of bone by switching off osteoclasts; they leave existing lesions largely as they are. This is why scans may not look dramatically better on treatment even when the drugs are doing their job of preventing new fractures.

The third is that bone protection is a substitute for treating the myeloma. It is not. The most powerful way to stop bone destruction is to reduce the number of abnormal plasma cells producing the signals that drive it. Supportive drugs work alongside that, never instead of it.

The fourth is that rest protects fragile bones. Prolonged rest weakens muscle and bone alike and raises the risk of clots. Movement, chosen and supervised appropriately, is protective.

The fifth is that any painkiller is fine as long as it is sold without a prescription. NSAIDs are widely available and widely used, yet they are among the medicines a myeloma team most often asks patients to avoid because of the kidneys.

The sixth is that a dentist’s chair is somewhere to avoid once bone-modifying treatment starts. The opposite is true: regular dental care is one of the main safeguards against jaw complications, and the dentist simply needs to know which drug is in use.

Questions to ask your care team

Clinic appointments move fast, and the questions that matter most are easy to forget in the moment. These are the ones that tend to unlock the most useful conversations about bone and kidney protection.

• Which of my bones show lesions or thinning on the latest scans, and are any of them at risk of fracture right now?
• Am I being offered a bone-strengthening medicine, and if so, which class and why that choice for me?
• How will you monitor my kidney function and calcium while I am on it, and what would prompt a change?
• Should I see a dentist before starting, and what should I tell them?
• Do I need calcium or vitamin D supplements at the moment, or should I wait for the next blood test?
• What is my daily fluid target, and does it change on treatment days or if I am unwell?
• Which painkillers can I take at home, and which should I avoid?
• Is there anything I should say before a CT scan or other imaging that uses contrast dye?
• Can I be referred to a physiotherapist who has experience with myeloma, and what movements should I avoid until I see them?
• Are there activities I should stop entirely for now, and when might we review that?
• Which symptoms should make me call the same day rather than wait for the next appointment?
• Who do I contact out of hours, and what number do I use?

Writing the answers down, or asking whether a relative can join the appointment, tends to make the information stick. Many teams also provide a written care plan that covers the fluid target, the painkiller advice and the emergency contact details in one place; it is worth asking for one if it has not been offered.

None of these questions has a universal answer. The point of asking is to hear the reasoning that applies to one particular person’s scans, blood results and life, which is the only reasoning that counts.

When to call your doctor

Most days with myeloma are uneventful, and the aim of this section is not to keep anyone on edge. A short list of signs, however, should trigger a same-day call to the hematology team or an emergency service, because each can point to a complication that responds better when treated quickly.

Call urgently, or go to an emergency department, for any of the following:

• Sudden severe back or neck pain, particularly with numbness, tingling or weakness in the legs or arms, or difficulty walking. These can signal spinal cord compression, which the NHS describes as a medical emergency.
• New difficulty controlling the bladder or bowel, or numbness around the buttocks or inner thighs.
• Sudden pain in a limb after minimal or no injury, or inability to bear weight, which may indicate a fracture.
• Marked thirst, passing large amounts of urine, constipation, nausea, confusion or unusual drowsiness, which together can indicate high blood calcium.
• Passing much less urine than usual, swelling of the ankles or face, or breathlessness, which may reflect worsening kidney function.
• A fever, shivering or feeling suddenly very unwell. Myeloma and its treatment suppress immunity, and infection can progress quickly.
• Unusual bruising or bleeding, or breathlessness on mild exertion.

A same-day or next-day call, rather than an emergency visit, is appropriate for bone pain that is new or changing in character, a sore or numb jaw, a loose tooth or exposed bone in the mouth, vomiting or diarrhea lasting more than a day, or a new prescription from another clinician that has not been checked against the myeloma plan.

Teams would rather hear about a symptom that turns out to be nothing than miss one that mattered. Every decision about what to do next, from imaging to admission, rests with the treating clinicians, and the patient’s role is simply to make the call early.

Frequently asked questions

Why does multiple myeloma bone pain often start in the back?

The spine is one of the sites where myeloma most often thins bone, and vertebrae carry the body’s weight all day, so damage there produces pain earlier and more persistently than in many other bones. The NHS lists back and rib pain among the common symptoms. New or worsening back pain, especially with numbness or weakness, should be reported to the treating team promptly rather than treated at home.

How do bisphosphonates for myeloma differ from denosumab?

Both slow the osteoclasts that dissolve bone, but by different routes. Bisphosphonates bind to bone mineral and are absorbed by osteoclasts, and they are cleared through the kidneys, so kidney function is checked before each infusion. Denosumab is an antibody that blocks the RANKL signal activating osteoclasts and is not kidney-cleared, though it can lower blood calcium. The choice between them rests with the hematology team.

Can myeloma kidney damage improve with treatment?

It often can, particularly when myeloma treatment begins promptly and the kidneys are kept well hydrated in the meantime. Kidney injury in myeloma is usually caused by light chain proteins forming casts in the tubules; as treatment lowers the light chain load, the tubules can recover. The degree of recovery varies between people and depends on how long and how severely the kidneys were affected, so the team tracks it through regular blood tests.

Is exercise with multiple myeloma safe if I have lytic lesions?

Usually yes, with limits set by a physiotherapist who has reviewed the scans. Walking, stationary cycling and swimming are commonly well tolerated, while heavy lifting, high-impact sport and loaded twisting of the spine are generally avoided or cleared individually. Lesions in weight-bearing bones such as the femur or spine may need stabilizing treatment before certain activities resume. Complete rest is not recommended, because it weakens muscle and bone and raises clot risk.

Should I take calcium supplements to protect my bones?

Only if the treating team advises it after checking blood levels. Active myeloma can raise blood calcium to dangerous levels, in which case extra calcium would be harmful, while bone-protecting drugs such as denosumab can lower calcium and make supplements necessary. The NIH Office of Dietary Supplements notes that vitamin D is needed to absorb calcium, so both are usually assessed together. The decision follows test results rather than a general rule.

Why do I need to see a dentist before starting bone treatment?

Because bisphosphonates and denosumab slow the bone remodeling the jaw relies on to heal after an extraction or other procedure, and a rare complication called osteonecrosis of the jaw can follow. Completing any necessary dental work before treatment begins, and keeping up regular dental care during it, lowers that risk. The dentist should be told which medicine is being used so that any future procedure can be planned with the hematology team.

Which painkillers are safe for the kidneys with myeloma?

Non-steroidal anti-inflammatory drugs, the class that includes ibuprofen and naproxen, are usually avoided because they reduce blood flow through the kidney’s filters. Acetaminophen, called paracetamol outside the US, is generally the preferred over-the-counter option, but the team should still know it is being taken. Prescription pain relief, including radiotherapy for painful bone lesions, is arranged by the treating clinicians, and any new medicine from another prescriber should be checked against the myeloma plan.

How much fluid should I drink each day?

The right amount is individual and should come from the treating team, because heart health, other conditions and current kidney function all affect it. The general principle, described by the NHS, is that plenty of fluid helps the kidneys pass light chain proteins through rather than letting them form blockages. Water and non-alcoholic drinks count; alcohol can dehydrate. On days of vomiting, diarrhea or fever, the team should be contacted because fluid needs change quickly.

Can a CT scan harm my kidneys if I have myeloma?

The concern is the iodinated contrast dye used in some CT scans and procedures, which is cleared by the kidneys and can worsen function in someone already at risk. It does not mean such scans are forbidden. The person ordering the scan should know about the myeloma so they can weigh alternatives, arrange extra fluids beforehand, or choose a protocol without contrast where that gives the information needed.

What symptoms mean I should call the same day?

Sudden severe back or neck pain, new weakness, numbness or tingling in the limbs, difficulty walking, or loss of bladder or bowel control need emergency attention because they can indicate spinal cord compression. Marked thirst, confusion, drowsiness or a sharp fall in urine output, fever or shivering, and sudden limb pain after minimal injury also warrant an immediate call. The treating team decides what happens next; the patient’s job is to make the call early.

References

• NHS: Multiple myeloma
• Cleveland Clinic: Multiple myeloma
• MedlinePlus: Multiple myeloma
• CDC: Physical activity guidelines for adults

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.